Demonstrates sustained activity of NOP receptor agonists, suggesting new drug development strategies.
High Resolution Image Download MS PowerPoint Slide The nociceptin/orphanin FQ (N/OFQ) receptor (NOP) ligands are drug candidates for different diseases, but peptide ligands are often limited by rapid enzymatic degradation and short in vivo duration of action. Here, we applied a multiple D-amino acid substitution strategy to the peptide template [Arg 14 Lys 15 ]N/OFQ(1-15)-NH 2 to improve metabolic stability while preserving receptor activity. Progressive substitutions revealed marked positional tolerance within the C-terminal address domain and identified [ d -Lys 13,15 d -Arg 14 ]N/OFQ(1–15)-NH 2 (compound 1c ) as the most promising compound. This led to the Cha 1 -containing analogue 3a, which retained full agonist efficacy and high selectivity at the NOP receptor in vitro and ex vivo . In vivo, compound 3a induced a long-lasting loss of the righting reflex in mice, closely overlapping the pharmacological profile of the potent and long-acting agonist UFP-112. These findings define the stereochemical tolerance of the NOP receptor toward multiple d -amino acid substitutions within the N/OFQ peptide and demonstrate that this information can be exploited as a rational design strategy to generate NOP receptor agonists with prolonged in vivo activity.
No takes yet. Share an insight, caveat, or question.
Sturaro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: